Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:GRTX NASDAQ:GTBP NASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.54-5.7%$0.70$0.48▼$2.48$15.72M1.03596,498 shs419,910 shsGRTXGalera Therapeutics$0.09+8.0%$0.09$0.02▼$0.15$14.73M2.59197,678 shs3,442 shsGTBPGT Biopharma$0.45+2.8%$0.40$0.26▼$3.85$15.69M0.861.79 million shs1.43 million shsPPBTPurple Biotech$1.58+2.6%$3.69$1.42▼$29.00$1.43M0.61862,512 shs354,545 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals+3.56%-2.87%-6.59%-40.49%-43.31%GRTXGalera Therapeutics-6.05%-16.20%-16.95%+78.30%+204.73%GTBPGT Biopharma+4.77%-8.81%+34.84%+4.95%-86.32%PPBTPurple Biotech-47.97%-50.16%-60.00%-62.44%-93.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.54-5.7%$0.70$0.48▼$2.48$15.72M1.03596,498 shs419,910 shsGRTXGalera Therapeutics$0.09+8.0%$0.09$0.02▼$0.15$14.73M2.59197,678 shs3,442 shsGTBPGT Biopharma$0.45+2.8%$0.40$0.26▼$3.85$15.69M0.861.79 million shs1.43 million shsPPBTPurple Biotech$1.58+2.6%$3.69$1.42▼$29.00$1.43M0.61862,512 shs354,545 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals+3.56%-2.87%-6.59%-40.49%-43.31%GRTXGalera Therapeutics-6.05%-16.20%-16.95%+78.30%+204.73%GTBPGT Biopharma+4.77%-8.81%+34.84%+4.95%-86.32%PPBTPurple Biotech-47.97%-50.16%-60.00%-62.44%-93.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.25Hold$5.00825.93% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AGTBPGT Biopharma 1.00SellN/AN/APPBTPurple Biotech 2.00Hold$30.001,798.73% UpsideCurrent Analyst Ratings BreakdownLatest PPBT, CTXR, GTBP, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026PPBTPurple Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/22/2026PPBTPurple Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/19/2026CTXRCitius Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.005/4/2026PPBTPurple Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/13/2026PPBTPurple Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026PPBTPurple Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/13/2026PPBTPurple Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $30.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AGTBPGT BiopharmaN/AN/A$0.02 per share29.08$0.23 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$7.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)GRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%8/12/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.33N/AN/AN/AN/AN/A-102.03%8/13/2026 (Estimated)PPBTPurple Biotech-$26.39M-$18.84N/AN/AN/AN/A-123.63%-98.72%8/5/2026 (Estimated)Latest PPBT, CTXR, GTBP, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2026Q1 2026PPBTPurple Biotech-$0.38-$0.09+$0.29$0.09N/AN/A5/15/2026Q2 2026CTXRCitius Pharmaceuticals-$0.2808-$0.95-$0.6693-$0.95$10.23 millionN/A5/15/2026Q1 2026GTBPGT Biopharma-$0.08-$0.11-$0.03-$0.11N/AN/A3/13/2026Q4 2025PPBTPurple Biotech-$3.40-$19.85-$16.45$200.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.580.16GRTXGalera TherapeuticsN/A9.749.74GTBPGT BiopharmaN/A4.144.14PPBTPurple BiotechN/A1.481.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%GRTXGalera Therapeutics50.77%GTBPGT Biopharma8.15%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals4.99%GRTXGalera Therapeutics12.90%GTBPGT Biopharma3.40%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2027.45 million26.08 millionOptionableGRTXGalera Therapeutics30160.43 million47.38 millionOptionableGTBPGT Biopharma836.06 million34.84 millionNo DataPPBTPurple Biotech20930,0001.25 millionOptionablePPBT, CTXR, GTBP, and GRTX HeadlinesRecent News About These CompaniesPurple Biotech presents new IM1240 preclinical data showing anti-tumor activity and broad therapeutic window (PPBT)June 12 at 1:24 AM | msn.comPurple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic WindowJune 11 at 10:20 AM | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Purple Biotech (PPBT), Satellos Bioscience (MSLE)May 19, 2026 | theglobeandmail.comPurple Biotech Reports First Quarter 2026 Financial Results and Business HighlightsMay 16, 2026 | markets.businessinsider.comPurple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240April 27, 2026 | markets.businessinsider.comPurple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformApril 23, 2026 | markets.businessinsider.comPurple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformMarch 25, 2026 | markets.businessinsider.comPurple Biotech Regains Compliance with NasdaqMarch 17, 2026 | finance.yahoo.comPurple Biotech Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 13, 2026 | markets.businessinsider.comPurple Biotech Announces CEO TransitionMarch 13, 2026 | globenewswire.comPurple Biotech Announces Plan to Implement ADS Ratio ChangeFebruary 25, 2026 | globenewswire.comShort Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9%February 18, 2026 | defenseworld.netDPurple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240January 7, 2026 | markets.businessinsider.comPurple Biotech’s antibody platform shows anti-tumor activityDecember 11, 2025 | msn.comPurple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025December 11, 2025 | markets.businessinsider.comPurple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual ...December 4, 2025 | markets.businessinsider.comPurple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual CongressDecember 4, 2025 | globenewswire.comPurple Biotech Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 14, 2025 | globenewswire.comPurple Biotech Announces Extraordinary General Meeting for December 2025November 3, 2025 | msn.comCancer Immunotherapy Innovators Break New Ground in Antibody EngineeringOctober 30, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPBT, CTXR, GTBP, and GRTX Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.54 -0.03 (-5.69%) Closing price 04:00 PM EasternExtended Trading$0.56 +0.02 (+4.07%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Galera Therapeutics NASDAQ:GRTX$0.09 +0.01 (+8.00%) As of 03:54 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.GT Biopharma NASDAQ:GTBP$0.45 +0.01 (+2.76%) Closing price 04:00 PM EasternExtended Trading$0.45 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Purple Biotech NASDAQ:PPBT$1.58 +0.04 (+2.60%) Closing price 04:00 PM EasternExtended Trading$1.56 -0.02 (-1.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
